Hemorheologic effects of vasodilation in essential hypertension

Angiology

Volumn 47, Issue 9, 1996, Pages 869-878

  Wysocki, Marian ^a   Andersson, Ove K ^a   Persson, Bengt ^a   Bagge, Ulf ^b   Braide, Magnus ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CADRALAZINE; PLACEBO;

ADULT; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHROCYTE DEFORMABILITY; ESSENTIAL HYPERTENSION; FLOW KINETICS; HEART OUTPUT; HEMOCONCENTRATION; HEMODILUTION; HUMAN; MALE; MICROCIRCULATION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE; VASODILATATION;

EID: 0029832192     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979604700905     Document Type: Article

References (44)

1. Tarazi RC: Hemodynamic role of extracellular fluid in hypertension. Circ Res 38:73-83, 1976.
2. Bing RF, Smith AJ: Plasma and interstitial volumes in essential hypertension: Relationship to blood pressure. Clin Sci 61:287-293, 1981.
3. Tibblin G, Bergenz S-E, Bjure J, et al: Hematocrit, plasma protein, plasma volume, and viscosity in early hypertensive disease. Am Heart J 72:165-176, 1966.
4. Chrysant SG, Frohlich ED, Adamopoulos PN, et al: Pathophysiologic significance of "stress" or relative polycythemia in essential hypertension. Am J Cardiol 37:1069-1072, 1976.
5. Dintenfass L: Hyperviscosity in Hypertension. Sydney: Pergamon Press, 1981.
6. Letcher RL, Chien S, Pickering TG, et al: Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Am J Med 70:1195-1202, 1981.
7. Isles C, Lowe GDO, Rankin BM, et al: Abnormal hemostasis and blood viscosity in malignant hypertension. Thromb Hemostas 52:253-255, 1984.
8. Petralito A: Erythrocyte aggregation in different stages of arterial hypertension. Thromb Hemostas 54:555, 1985.
9. Freitas J, Braz-Nogueira J, Nogueira da Costa J, et al: Whole blood filterability and blood oxygen transport in human hypertension. Clin Hemorheol 3:367-373, 1983.
10. Wysocki M, Grajek S, Bagge U, et al: Relationships between hemodynamic indices and rheological properties of blood in primary hypertension. Clin Hemorheol 8:113-127, 1988.
11. Devereux RB, Drayer JI, Chien S, et al: Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 54:592-595, 1984.
12. Chien S: Hemorheology in disease: Pathophysiological significance and therapeutic implications. Clin Hemorheol 1:419-442, 1981.
13. Van Zwieten PA: Vasodilator drugs with direct action on smooth muscle. In: Handbook of Hypertension, Vol. 3, Pharmacology of Antihypertensive Drugs, ed. by van Zwieten PA. Amsterdam: Elsevier, 1984, pp 307-330.
14. Letcher RL, Chien S, Laragh JH: Changes in blood viscosity accompanying the response to prazosin in patients with essential hypertension. J Cardiovasc Pharmacol 1 (suppl):s8-s20, 1979.
15. De Cree J, Leempoels J, Guekens H, et al: Are serotoninergic mechanisms involved in high blood pressure? In: 5-Hydroxytryptamine in Peripheral Reactions, ed. by De Clerck F, Vanhoute PM. New York: Raven Press, 1982, pp 183-192.
16. Wellens D, Gossens T, Reytjens A: Positive hemokinetic effects after selective calcium antagonsim. Angiology 31:821-827, 1980.
17. Hopkins RJ, Hill TWK: Effects of felodipine on red blood cell deformability. Drugs 29 (suppl 2):42-44, 1985.
18. Koenig W, Ernst E: The effects of calcium channel blockers on blood fluidity. J Cardiovasc Pharmacol 6 (suppl 6):s40-s44, 1990.
19. Wysocki M, Persson B, Bagge U, et al: Flow resistance and its components in hypertensive men treated with the calcium antagonist isradipine. Eur J Clin Pharmacol 43:463-468, 1992.
20. Semeraro C, Dorigotti L, Banfi S, et al: Pharmacological studies on cadralazine: A new antihypertensive vasodilator drug. J Cardiovasc Pharmacol 3:455-467, 1981.
21. McTavish D, Young RA, Clissold SP: Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 40:543-560, 1990.
22. Persson B, Granerus G, Wysocki M, et al: Acute systemic and renal hemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics. Eur J Clin Pharmacol 31:513-518, 1987.
23. Nilsson NJ: A linearly responding dichromatic cuvette densitometer for dye-dilution curves. Scand J Clin Lab Invest 15 (suppl 69):181-193, 1963.
24. Ferguson JJ, Randall OS: Hemodynamic correlates of arterial compliance. Cathet Cardiovasc Diagn 12:376-380, 1986.
25. Wells RE, Denton R: Measurement of viscosity of biological fluids by cone-plate viscometer. J Lab Clin Med 57:646-656, 1961.
26. Jan KM, Chien S: Effect of hematocrit variations on coronary hemodynamics and oxygen utilization. Am J Physiol 233:H106-H113, 1977.
27. Erslev A, Caro J: Secondary polycythemia: A boon or a burden? Blood Cells 10:177-191, 1984.
28. Kato T, Tsushima N: Changes in blood rheologic factors following coronary artery surgery. J Surg Res 51:128-132, 1991.
29. Kato T, Shunki Y, Kako T, et al: Effect of nifedipine on oxygen delivery in patients with angina pectoris: Relation between blood viscosity and hematocrit. J Clin Pharmacol 31:518-520, 1991.
30. Melkumyants AM, Balashov SA, Khayutin VM: Endothelium dependent control of arterial diameter by blood viscosity. Cardiovasc Res 23:741-747, 1989.
31. Levenson J, Flaud P, Del Pino M, et al: Blood viscosity as a chronic contributing factor of vasodilatation in humans. J Hypertens 8:1049-1055, 1990.
32. Charlesworth D: Relationships of blood rheology to blood flow. In: Clinical Aspects of Blood Viscosity and Cell Deformability, ed. by Lowe GDO, Barbanel JC, Forbes CD. Berlin: Springer-Verlag, 1981, pp 91-96.
33. Spence JD: Effects of antihypertensive agents on blood velocity: Implications for atherogenesis. Can Med Assoc J 127:721-724, 1982.
34. Brügger W, Imhof P, Müller P, et al: Effect of nitro-glycerin on blood rheology in healthy subjects. Eur J Clin Pharmacol 29:331-336, 1985.
35. Pedrinelli R, Graziadei L, Panarace G, et al: Regional and systemic hemodynamic and humoral effects of transdermal nitroglycerin in mild hypertension. J Cardiovasc Pharmacol 14:636-641, 1989.
36. Walker RT, Matrai A, Bogar L, et al: Serotonin and the flow properties of blood. J Cardiovasc Pharmacol 7 (suppl 7):S35-S37, 1985.
37. Redmayne GN, Aves EK, Sanford J: The comparative effects of three vasoactive componds (oxypentifylline, prazosin and indoramin) on the blood rheology of beagle dogs. Clin Hemorheol 5:301-309, 1985.
38. Eisenberg S, Klein GF, Wolf PS: Dynamics of the splenic erythrocyte reservoir in the dog. J Surg Res 9:595-604, 1969.
39. Ayers AB, Davies BN, Withrington PG: Responses of isolated, perfused human spleen to sympathetic nerve stimulation, catecholamines and polypeptides. Br J Pharmacol 44:17-30, 1972.
40. Bell L, Zaret BL, Rutlen DL: Influence of alpha-adrenergic receptor stimulation on splanchnic intravascular volume in conscious humans. Acta Physiol Scand 143:65-69, 1991.
41. Laub M, Hvid-Jacobsen K, Hovind P, et al: Spleen emptying and venous hematocrit in humans during exercise. J Appl Physiol 74:1024-1026, 1993.
42. Semplicini A, Pessina AC, Caregaro L, et al: Blood pressure, body fluids and renal tubular handling of sodium during cadralazine plus atenolol treatment in essential hypertension. Curr Ther Res 34:1038-1043, 1983.
43. Ibsen H, Rasmussen K, Aerenlund Jensen H, et al: Changes in plasma volume and extracellular fluid volume after addition of hydralazine to propranolol treatment in patients with hypertension. Acta Med Scand 203:419-423, 1978.
44. Hutchins PM, Marshburn TH, Maultsby SJ, et al: Long-term microvascular response to hydralazine in spontaneously hypertensive rats. Hypertension 12:74-79, 1988.